Introduction. Parkinson's disease (PD) is a chronic condition belonging to the group of non-neurodegenerative diseases. The core of the clinical picture of PD is hypokinesia, as well as resting tremor, increased muscle tone, and postural instability as the disease progresses. In accordance with clinical recommendations, the main six groups of Antiparkinsonian drugs are used. Drug therapy is differentiated and personalized depending on the stage of the disease and clinical manifestations. Goal. Analysis of pharmacotherapy in the personalized management of PD patients depending on the stage and clinical picture of the disease. Materials and methods. The study was performed on the basis of GBUZ "City Polyclinic No. 2 of the Moscow Department of Health" (hereinafter – GBUZ "GP No. 2 DZM"). Drug therapy was analyzed. The analysis of medical documentation regarding pharmacotherapy was carried out in 410 patients with PD, of whom 254 (62%) were men and 156 (38%) were women, the average age was 66.2+7.8 years, with an average duration of the disease of 66+45 months (5.6 + 3.9 years). Results. The results of the study indicate that patients with stages 3 and 2 according to Hyun and Yaru were the leaders in terms of the severity of the disease. Pharmacotherapy analysis showed that 349 (85.7%) and 218 (53.2%) dopamine receptor agonist drugs were prescribed in patients with initial (1-2 stages) of the disease, respectively. Monotherapy in the initial stages in 89 (73%) patients, less than 106 (66%) combined. In advanced stage 3, combination therapy based on levodopa 188 (100%) drugs took place in 100% of cases. Discussions. The results obtained in this study confirm that PD is an age-related disease. Of the six registered groups of antiparkinsonian drugs, drugs are actively prescribed: dopaminergic receptor agonists, amantadine, levodopa drugs. Monotherapy was used in the early stages (1st and 2nd ct), in the vast majority of cases (80%) combination therapy. The most commonly used drugs are dopamine receptor agonists, followed by levodopa drugs, followed by amantadine drugs. Conclusions. Parkinson's disease is a chronic neurodegenerative disease that requires regular intake of antiparkinsonian medications. The features of the clinical picture and stage of the disease affect the choice of medications, and knowing the "point" of application of each drug to the leading symptom increases the effectiveness and adherence to therapy. In the early stages, the appointment of dopaminergic receptor agonists and amantadine drugs prevails, with an increase in the duration and stage of the disease, levodopa drugs are involved, this group belongs to the Gold standard in the treatment of PD. The data obtained are important for planning the drug supply for PD patients.